Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

Leukemia. 2014 Jan;28(1):179-82. doi: 10.1038/leu.2013.232. Epub 2013 Aug 8.

Authors

L R Martins¹, P Lúcio², A Melão¹, I Antunes¹, B A Cardoso¹, R Stansfield³, M T S Bertilaccio⁴, P Ghia⁵, D Drygin³, M G Silva², J T Barata¹

Affiliations

¹ Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.
² CEDOC, Faculdade de Ciências Médicas, FCM, Universidade Nova de Lisboa and Instituto Português de Oncologia, Lisbon, Portugal.
³ Cylene Pharmaceuticals, San Diego, CA, USA.
⁴ Istituto Scientifico San Raffaele, Milano, Italy.
⁵ 1] Istituto Scientifico San Raffaele, Milano, Italy [2] Università Vita-Salute San Raffaele, Milano, Italy.

PMID: 23925046
DOI: 10.1038/leu.2013.232

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Naphthyridines / therapeutic use*
Phenazines

Substances

Antineoplastic Agents
Naphthyridines
Phenazines
silmitasertib